Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas

Stem Cells

Volumn 26, Issue 12, 2008, Pages 3018-3026

  Xu, Qijin ^a   Yuan, Xiangpeng ^a   Liu, Gentao ^a   Black, Keith L ^a   Yu, John S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer stem cells; Glioblastoma; Hedgehog; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLOPAMINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B INHIBITOR; SONIC HEDGEHOG PROTEIN;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN STEM; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEDGEHOG PROTEINS; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

ERINACEIDAE; MAMMALIA; MUS;

EID: 58049193929     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0459     Document Type: Article

References (48)

1. Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23:9392-9400.
2. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
3. Tang DG, Patrawala L, Calhoun T et al. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol Carcinog 2007;46:1-14.
4. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115.
6. Liao MJ, Zhang CC, Zhou B et al. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res 2007;67:8131-8138.
7. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563.
8. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
9. Lee J, Kotliarova S, Kotliarov Y et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.
10. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-2710.
11. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-765.
12. Phillips HS, Kharbanda S, Chen RH et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-173.
13. Dahmane N, Sanchez P, Gitton Y et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001;128:5201-5212.
14. Katayam M, Yoshida K, Ishimori H et al. Patched and smoothened mRNA expression in human astrocytic tumors inversely correlates with histological malignancy. J Neurooncol 2002;59:107-115.
15. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024.
16. Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002;1:269-277.
17. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349.
18. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006;51:187-199.
19. Ligon KL, Huillard E, Mehta S et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007;53:503-517.
20. Clement V, Sanchez P, de Tribolet N et al. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-172.
21. Sanchez P, Hernandez AM, Stecca B et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101:12561-12566.
22. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
23. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-127.
24. Ito D, Fujimoto K, Mori T et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006;118:2337-2343.
25. Mungamuri SK, Yang X, Thor AD et al. Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715-4724.
26. Dragowska WH, Verreault M, Yapp DT et al. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: Therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat 2007;106:319-331.
27. Creighton CJ. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene 2007;26:4648-4655.
28. Masiello D, Mohi MG, McKnight NC et al. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther 2007;6:195-201.
29. Li D, Shimamura T, Ji H et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007;12:81-93.
30. Horvath S, Zhang B, Carlson M et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 2006;103:17402-17407.
31. Liang Y, Diehn M, Watson N et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102:5814-5819.
32. Mischel PS, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003;22:2361-2373.
33. Leung C, Lingbeek M, Shakhova O et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004;428:337-341.
34. Rao G, Pedone CA, Valle LD et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 2004;23:6156-6162.
35. Romer JT, Kimura H, Magdaleno S et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004;6:229-240.
36. Kimura H, Stephen D, Joyner A et al. Gli1 is important for medulloblastoma formation in Ptc1+/- mice. Oncogene 2005;24:4026-4036.
37. Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. STEM CELLS 2007;25:2524-2533.
38. Nery S, Wichterle H, Fishell G. Sonic hedgehog contributes to oligodendrocyte specification in the mammalian forebrain. Development 2001;128:527-540.
39. Lu QR, Yuk D, Alberta JA et al. Sonic hedgehog-regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000;25:317-329.
40. Ehtesham M, Sarangi A, Valadez JG et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 2007;26:5752-5761.
41. Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidyl-inositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63:2742-2746.
42. Backman SA, Ghazarian D, So K et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci U S A 2004;101:1725-1730.
43. Cully M, Elia A, Ong SH et al. grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice. Proc Natl Acad Sci U S A 2004;101:15358-15363.
44. Okumura K, Zhao M, Depinho RA et al. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci U S A 2005;102:2703-2706.
45. Chang SM, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004;22:427-435.
46. Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23:357-361.
47. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-5304.
48. Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101-112.